Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

245
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
245
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

408
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
408
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

755
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac energetics in health and disease: a meta-analysis.

European heart journal. Imaging methods and practice·2026
Same author

Severe Aortic Stenosis Is Associated With Left Atrial Prothrombotic Flow That Persists Despite Valve Replacement.

Journal of the American Heart Association·2026
Same author

IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.

Circulation·2025
Same author

Cardiac energetics in severe mitral regurgitation: relationship with eccentric hypertrophy, stroke volume, and effects of valve repair.

European heart journal. Imaging methods and practice·2025
Same author

A double-blind, randomized placebo-controlled trial examining the effect of MitoQ on myocardial energetics in patients with dilated cardiomyopathy.

European heart journal. Cardiovascular Imaging·2025
Same author

Safety and Feasibility of Magnetic Resonance Imaging Within the First Week Following Transvenous Pacing System Implantation.

Circulation·2025

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

Targeting Obesity for Heart Failure.

Emily Morris1, Oliver Rider1

  • 1Oxford Centre for Magnetic Resonance Research, University of Oxford Oxford, UK.

European Cardiology
|January 12, 2026
PubMed
Summary

Obesity significantly contributes to heart failure (HF). Intentional weight loss interventions, including bariatric surgery and GLP-1 agonists, show promise for improving cardiac health and outcomes in patients with obesity and HF.

Keywords:
Heart failureobesityweight loss

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

895
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.3K

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

895
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.3K

Area of Science:

  • Cardiology
  • Metabolic Health
  • Obesity Medicine

Background:

  • Obesity is a global health crisis, increasingly linked to heart failure (HF) incidence and progression.
  • The relationship between obesity and HF is complex, influenced by haemodynamic, metabolic, and inflammatory pathways.
  • The 'obesity paradox' presents challenges in understanding prognosis for individuals with established HF and obesity.

Purpose of the Study:

  • To review the bidirectional relationship between obesity and heart failure.
  • To summarize evidence on the impact of intentional weight loss on cardiac structure, function, and clinical outcomes in HF patients.
  • To explore the efficacy of various weight loss interventions for managing obesity in the context of heart failure.

Main Methods:

  • Literature review synthesizing current research on obesity and heart failure.
  • Analysis of evidence from studies on bariatric surgery, dietary interventions, pharmacological treatments (e.g., GLP-1 receptor agonists), and exercise programs.
  • Examination of clinical outcomes, cardiac structure, and function in relation to weight loss interventions.

Main Results:

  • Bariatric surgery demonstrates consistent benefits for heart failure patients across different phenotypes.
  • Pharmacological interventions, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, show potential for cardiometabolic improvements.
  • Structured exercise and rehabilitation programs also show emerging benefits for managing obesity in heart failure.

Conclusions:

  • Targeting obesity is crucial for improving morbidity and mortality in high-risk heart failure populations.
  • Further research is needed to clarify long-term intervention efficacy and the combined benefits of therapies like GLP-1 receptor agonists and SGLT2 inhibitors.
  • Intentional weight loss strategies offer a promising avenue for managing heart failure in the context of the growing obesity epidemic.